top of page
BRAIN LOGO SUNSET.png

Evidence-Based Approach to Suboxone Therapy for Opioid Use Disorder (OUD)

This step-by-step guide follows evidence-based guidelines from SAMHSA, ASAM, and clinical research for induction, stabilization, maintenance, and monitoring during Suboxone (buprenorphine/naloxone) therapy.

1. How Suboxone Works


Suboxone (buprenorphine/naloxone) is a partial opioid agonist, reducing cravings and withdrawal symptoms without producing full opioid effects.

  • Buprenorphine: Partial agonist, high binding affinity, prevents euphoria.

  • Naloxone: Opioid antagonist, active only if injected or snorted.

Onset & Duration:

  • Sublingual tablet/film: Onset 30-60 min, peak 1-4 hrs, lasts 24-48 hrs.

  • Bioavailability: Sublingual: ~30-50%, IV: ~100% (risk of misuse).

2. Patient Eligibility & Pre-Assessment


Essential Assessments:

  • Opioid dependence (history, urine drug screen, prescription monitoring)

  • Withdrawal status (COWS ≥ 8-12)

  • Medical & psychiatric history

  • Contraindications (severe respiratory issues, intoxication, allergies)

Baseline Labs:

  • Urine Drug Screen (UDS)

  • Liver Function Tests (LFTs)

  • Comprehensive Metabolic Panel (CMP)

  • Complete Blood Count (CBC)

  • Hepatitis Panel (A, B, C)

  • HIV Test

  • Pregnancy Test (if applicable)

  • Testosterone Levels (if indicated)

  • ECG (if history of cardiac issues or methadone use)

Handling Patient Lab Refusal:

  • Document informed consent clearly.

  • Monitor closely for side effects (hepatic impairment, sedation, respiratory depression).

  • Start cautiously and titrate doses carefully.

3. Induction Phase

Timing:

  • Begin when moderate withdrawal (8-12 hrs post short-acting opioids, 24-72 hrs post long-acting opioids).

Induction Protocol:

COWS ScoreInitial DoseTitration Schedule8-12 (mild-mod withdrawal)2-4 mg SLObserve 1-2 hrs, repeat 2-4 mg if needed>12 (mod-severe withdrawal)4-8 mg SLRepeat up to 8 mg first 24 hrs (max 12-16 mg)24 hrs post-inductionTarget 12-16 mg/dayAdjust based on symptoms

  • If withdrawal resolves: Effective.

  • If worsens: Treat precipitated withdrawal symptomatically (clonidine, hydroxyzine).

4. Stabilization & Maintenance (Weeks 1-4)

  • Goal: Stable daily dose.

  • Typical Dose: 8-16 mg/day (max 24 mg/day).

  • Monitoring: Every 2-3 days initially, then weekly.

Dosing Effectiveness:

  • Effective: No withdrawal or cravings.

  • Under-dosing: Continued symptoms, opioid or benzo use.

  • Over-dosing: Sedation, dizziness, slurred speech, shallow breathing.

5. Using Subutex (Buprenorphine Monotherapy)

Indications:

  • Pregnancy

  • Naloxone allergy/adverse reactions

  • Severe liver disease

  • Extreme sensitivity to naloxone

Dosing:

  • Same protocol as Suboxone.

6. Adjunctive Treatments

  • Clonidine (0.1-0.3 mg every 6-8 hrs)

  • Hydroxyzine (25-50 mg PRN)

  • Loperamide (initial 4 mg, then 2 mg PRN)

  • Ondansetron (4 mg every 8 hrs PRN)

  • Naloxone (nasal spray, 4 mg for overdose reversal)

Psychosocial Support:

  • Cognitive Behavioral Therapy (CBT)

  • Motivational Interviewing (MI)

  • Support Groups (NA, SMART Recovery)

7. Long-Term Treatment & Tapering

  • Maintenance Duration: Typically 6-12 months or longer (2-4 mg/day).

  • Tapering Protocol: Reduce by 2 mg every 1-2 weeks; slower tapers reduce relapse risk.

  • Relapse Risk: 50-90% within a year if abruptly stopped.

8. Follow-Up & Monitoring

Schedule:

  • Induction: Daily/weekly until stable

  • Stabilization: Weekly

  • Maintenance: Every 2-4 weeks, long-term monthly/quarterly

Regular Monitoring:

  • Urine Drug Screens (UDS)

  • Adherence and psychosocial evaluation

  • Signs of misuse (e.g., lost medication requests)

9. Summary Flowchart for Suboxone Therapy

  1. Confirm opioid dependence.

  2. Begin induction at COWS ≥8-12.

  3. Initial dose: 2-4 mg SL, adjust to 8-16 mg/day.

  4. Stabilize over 1-4 weeks.

  5. Adjust dosing based on symptoms.

  6. Taper gradually as appropriate.

Suboxone Prescribing Cheat Sheet (Clinicians)

Induction Phase:

COWS ScoreInitial DoseMax Day 1 Dose8-122-4 mg SL8-12 mg>124-8 mg SL12-16 mg

  • Target dose from day 2: 12-16 mg/day, max 24 mg/day.

Stabilization:

  • Adjust dose every 3-7 days.

  • Common doses: 8-24 mg/day.

Maintenance:

  • Stable dose typically 8-16 mg/day.

  • Follow-up every 2-4 weeks.

Tapering:

DoseReduction StepsInterval16 mg/day2-4 mg1-2 weeks8 mg/day2 mg1-2 weeks4 mg/day1 mg1-2 weeks2 mg/day0.5-1 mg1-2 weeks

  • Add clonidine (0.1 mg PRN) if withdrawal emerges.

Medical Contraindications:

Absolute:

  • Severe respiratory insufficiency

  • Severe hepatic impairment

  • Acute/severe asthma

  • Hypersensitivity to components

Relative:

  • Moderate hepatic impairment

  • Concurrent CNS depressants (benzodiazepines, alcohol)

  • Severe sleep apnea

  • Severe renal impairment

  • Prostatic hypertrophy

  • Increased intracranial pressure

  • Hypothyroidism

  • Adrenal insufficiency

Special Considerations:

  • Pregnancy/lactation

  • Older age

  • Psychiatric conditions

Opioid Conversion to Suboxone:

  • Morphine 30 mg oral ≈ 4-6 mg Suboxone

  • Oxycodone 20 mg oral ≈ 4-6 mg Suboxone

  • Hydrocodone 30 mg oral ≈ 4-6 mg Suboxone

  • Fentanyl 25 mcg/hr patch ≈ 12-16 mg Suboxone

  • Methadone 30-40 mg oral ≈ 8-12 mg Suboxone (complex, careful monitoring required)

Patient Education Essentials:

  • Take daily, sublingually.

  • Avoid alcohol, benzodiazepines, opioids.

  • Expect initial mild withdrawal; improvement within an hour.

  • Side effects: sedation, constipation, nausea.

  • Follow-up regularly; UDS required.

  • Taper gradually with professional guidance.

bottom of page